What The Pfizer Foundation does

The Pfizer Foundation is the charitable organization established by Pfizer Inc., focused on advancing global health equity and patient access to medicines. The Foundation's programmatic footprint spans three primary pillars: (1) the Pfizer RxPathways patient assistance program, which has operated for over 25 years providing insurance counseling, co-pay assistance, and free or discounted medicines to millions of uninsured and underinsured US patients; (2) the Accord for a Healthier World initiative, launched in 2022-05, which delivers Pfizer's full portfolio of medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries through partnerships with governments and global health organizations; and (3) the Global Health Fellows program, deploying skills-based volunteering and capacity-building partnerships with organizations including PharmAccess (Ghana, Tanzania), North Star Alliance (Kenya), Health Builders (Rwanda), Save the Children, the Infectious Diseases Institute (Uganda), IFPW Foundation, and The Leo Project, with the STEP 2.0 supply-chain training program spanning India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.

The Foundation leverages Pfizer Inc.'s biopharmaceutical infrastructure — headquartered at 66 Hudson Boulevard East, New York, with 10,000+ employees and 1,500 R&D scientists supporting a 96-candidate pipeline (35 Phase 1, 25 Phase 2, 31 Phase 3, 5 Registration) across Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines. Marketed products made available through Foundation programs include IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), HYMPAVZI (marstacimab), ELREXFIO (elranatamab-bcmm), LITFULO (ritlecitinib), NURTEC (rimegepant), TALZENNA (talazoparib), XTANDI (enzalutamide), and ABRYSVO (RSV vaccine). The Foundation also funds cancer-equity initiatives, including the Change the Odds partnership with the American Cancer Society, the SPARC MBC Challenge with UICC ($760,000 in grants to 20 organizations across 18 countries), and grants to Susan G. Komen and the Avon Foundation.

As a charitable entity (private, non-publicly traded), the Foundation operates on grant inflows rather than product revenue. Its leadership includes Caroline Roan, Vice President of Corporate Responsibility and President of the Pfizer Foundation. The Foundation's strategic role is to extend the reach of Pfizer Inc.'s commercial pharmaceutical portfolio into underserved populations, complementing the parent's commercial revenue model (pharmaceutical product sales distributed via field sales, PfizerPro for healthcare professionals, PfizerForAll for consumers, and a global distributor network). Note: significant data in this dossier pertains to Pfizer Inc. rather than the Foundation directly; the Foundation's own financials, headcount, and operational metrics are not separately disclosed in the provided sources.

Name

The Pfizer Foundation

Legal name

Pfizer Inc.

Website

https://pfizer.com

Company type

Public

Founded year

1849

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Pfizer Foundation is the charitable arm of Pfizer Inc., advancing global health equity through the 25+ year Pfizer RxPathways patient assistance program, the Accord for a Healthier World initiative serving 1.2 billion people across 45 lower-income countries, and Global Health Fellows partnerships across Africa and Asia.

Ownership category

akta.pro rank

Product category

Corporate Philanthropy & Health Grants

NAICS

Grantmaking Foundations (813211), Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)

akta.pro primary industry

International Grantmaking & Development Foundations (BPAGAKAH)

akta.pro secondary industries

Medical Missions & Global Health NGOs (BPAGACAI), Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Global health equity programs
• Health-focused philanthropy
• Patient advocacy grants
• Corporate charitable foundation
• Capacity building partnerships

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Pfizer generates revenue through the sale of prescription pharmaceutical products and vaccines. Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Core offering

The Pfizer Foundation is a corporate charitable organization that funds and operates global health equity programs, multi-year grant initiatives, and skills-based volunteering deployments (Global Health Fellows) in partnership with NGOs, patient advocacy organizations, and ministries of health across multiple countries. Its portfolio spans cancer disparities funding, patient advocacy grants, infectious disease capacity building, and supply chain training in lower-income countries.

Product overview

Pfizer is a biopharmaceutical company that discovers, develops, and commercializes medicines and vaccines across four key therapeutic areas: Inflammation & Immunology, Internal Medicine (including cardiovascular and metabolic diseases), Oncology, and Vaccines. The company's product portfolio consists of marketed products (including IBRANCE, PADCEV, TUKYSA, HYMPAVZI, ELREXFIO, LITFULO, NURTEC, TALZENNA, XTANDI, and ABRYSVO) and a robust pipeline of investigational candidates in various phases of clinical development. Pfizer also operates patient support programs (Pfizer RxPathways) and digital platforms (PfizerForAll for patients, PfizerPro for healthcare professionals) to support access to medicines and health information.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Health Fellows Program Skills-based volunteering program that places Pfizer employees with partner NGOs and health systems in lower-income countries to support public health insurance implementation, mobile health service delivery, health workforce training, data visualization, and infectious disease capacity building. Partners include PharmAccess, North Star Alliance, Health Builders, Save the Children, Infectious Diseases Institute, and The Leo Project.
• Change the Odds Initiative Three-year initiative co-funded with the American Cancer Society to address cancer disparities and improve health outcomes in medically underrepresented US communities. The program sits at the intersection of Foundation grantmaking and Pfizer's oncology equity agenda.
• SPARC MBC Challenge Grant program with the Union for International Cancer Control (UICC) that funds organizations addressing metastatic breast cancer. The Challenge awarded $760,000 in grants to 20 organizations from 18 countries, supporting a previously underserved population in cancer advocacy funding.
• Komen Disparities Support Program Grant-funded program with Susan G. Komen to reduce disparities in breast cancer outcomes between African-American and Caucasian women in the United States through targeted support of the Komen Disparities initiative.
• STEP 2.0 Supply Chain Training Program Supply chain training program delivered with IFPW Foundation that coaches healthcare supply chain professionals across India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia. Designed to strengthen pharmaceutical distribution and medicine availability capability in emerging markets.
• Patient Access Sponsorship (Pfizer RxPathways Foundation Support) Foundational philanthropic support for Pfizer's RxPathways patient assistance platform. Provides insurance counseling, co-pay help, and free or discounted medicines to millions of eligible uninsured and underinsured patients, operating for 25+ years.

Quantifiable outcome

• Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.
• +2 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

18 partnerships are on record, tiered core, major and minor.

• BioNTechcoreStrategic or Co-development Partner · 1 May 2026Collaboration on COVID-19 vaccine development and distribution. Pfizer and BioNTech co-developed the Pfizer-BioNTech COVID-19 Vaccine using mRNA technology. The partnership continues with COVID-19 vaccine development for children (6 months through 11 years of age).
• Astellas PharmacoreStrategic or Co-development Partner · 1 May 2026Co-development agreement for PADCEV (enfortumab vedotin) for muscle-invasive bladder cancer (EV-303, EV-304 studies).
• ValnevacoreStrategic or Co-development Partner · 1 January 2026Co-development of Lyme Disease Vaccine Candidate (PF-07307405) through the VALOR clinical trial program.
• Accord for a Healthier World Partners (45 Lower-Income Countries)coreStrategic or Co-development Partner · 1 May 2022Pfizer is working with governments, the global health community, and others who share commitment to advancing health equity. Offering full portfolio of medicines and vaccines for which Pfizer has global rights on a not-for-profit basis to 1.2 billion people in 45 lower-income countries.
• Patient Advocacy OrganizationsmajorGTM or Marketing PartnerPfizer supports organizations focusing on prescription access and provides grants to fund essential programs and services for patients coping with various cancers. In 2014, donated $6.3 million to US co-pay foundations for life-saving cancer medicines.
• PharmAccessmajorStrategic or Co-development PartnerGlobal Health Fellows partnership with PharmAccess in Ghana and Tanzania to support implementation of public health insurance programs and health equity funds to reach at-risk populations.
• North Star AlliancemajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Kenya to improve healthcare access through mobile health services for mobile and migrant populations.
• Health BuildersmajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Rwanda to strengthen health systems through training and capacity building.
• Save the ChildrenmajorStrategic or Co-development PartnerGlobal Health Fellows partnership to improve child health outcomes through skills-based volunteering and capacity building.
• Infectious Diseases Institute (Uganda)majorStrategic or Co-development PartnerGlobal Health Fellows partnership in Uganda to strengthen infectious disease treatment and research capacity.
• IFPW FoundationmajorStrategic or Co-development PartnerPartnership through Strategic Training Executive Program (STEP 2.0) to provide coaching to supply chain healthcare professionals in India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.
• The Leo ProjectmajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Kenya supporting a community-based organization through data visualization training and dashboard creation for tracking performance indicators.
• Change the Odds: American Cancer Society and PfizermajorStrategic or Co-development PartnerThree-year initiative aimed at addressing cancer disparities and improving health outcomes in medically underrepresented communities across the United States.
• Union for International Cancer Control (UICC)majorStrategic or Co-development PartnerFirst-of-its-kind initiative to address unique challenges facing metastatic breast cancer patients. SPARC MBC Challenge awarded $760,000 in grants to 20 organizations from 18 countries.
• Susan G. KomenminorGTM or Marketing PartnerSupported Komen Disparities initiative to reduce difference in breast cancer outcomes between African-American and Caucasian women in the US.
• AVON Foundation for WomenminorGTM or Marketing PartnerGrants program supporting people living with metastatic breast cancer. In 2015, Avon and Pfizer each contributed $500,000 in grants awarded to 23 nonprofit organizations.
• Cancer Support Community / The Leukemia & Lymphoma SocietyminorStrategic or Co-development PartnerCollaboration with Chronic Myeloid Leukemia (CML) Patient Experience Registry to identify and understand psychosocial and emotional needs of CML patients.
• ASCO/Conquer Cancer FoundationminorStrategic or Co-development PartnerSupported CancerLinQ initiative, a health information technology platform designed to improve quality and value of cancer care.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bristol Myers Squibb Foundation: Corporate foundation of a major global biopharma, focused on health equity and serious disease grantmaking. Operates disease-focused programs (cancer, cardiovascular, immunology) in underserved populations — directly comparable in scope, structure, and mission to the Pfizer Foundation.
• Johnson & Johnson Foundation: Corporate foundation of a top-3 global pharma/medtech company. Runs global health workforce, patient access, and frontline health worker programs internationally — the closest peer in scale and global health footprint.
• Merck Foundation: The philanthropic arm of Merck & Co., focused on health equity, cancer, infectious disease, and health workforce capacity-building in lower-income countries. Operates Global Health Fellows-like programs and aligns closely with Pfizer Foundation's model.
• Eli Lilly Foundation: Corporate foundation of Eli Lilly, focused on diabetes/obesity, oncology, and health equity. Comparable mid-to-large biopharma corporate foundation with patient access and disease-state grantmaking.
• Novartis Foundation: Foundation of Novartis focused on reimagining healthcare delivery in low- and middle-income countries through innovative programs (e.g., chronic disease management). Direct peer in international health equity grantmaking.
• GSK Foundation: Corporate foundation of GSK focused on global health, vaccines access, and health system strengthening in lower-income countries. Highly comparable in mission, scale, and partnership model.
• Roche Foundation: Corporate foundation of Roche focused on health equity, oncology access, and health systems in lower-income countries. Comparable in oncology-heavy grantmaking and global health footprint.
• Sanofi Foundation: Corporate foundation of Sanofi with international health equity programs, patient assistance, and capacity-building initiatives. Mid-tier biopharma corporate foundation comparable to the Pfizer Foundation in scope.
• AbbVie Foundation: Corporate foundation of AbbVie with patient assistance and health equity programs focused on oncology, immunology, and neuroscience. Direct peer in pharma corporate giving structure.

Broad incumbents

• Bill & Melinda Gates Foundation: The world's largest health-focused philanthropy with a $70B+ endowment and deep focus on global health equity, vaccine access, and infectious disease in lower-income countries. Operates at a much larger scale than any corporate pharma foundation but addresses the same end beneficiaries.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Pfizer
• YouTubeyoutube.com/Pfizer
• Facebookfacebook.com/Pfizer
• LinkedInlinkedin.com/company/pfizer
• Instagraminstagram.com/pfizerinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Pfizer Foundation